Hospital stocks have fallen sharply after the Supreme Court questioned steep markups on cancer drugs and asked the government to examine allegations that hospitals require patients to buy medicines from their own or designated pharmacies. The market reaction has focused on earnings, but the larger issue is how India’s hospital system prices medicines, devices and consumables at the point where patients are most financially vulnerable.
According to the Economic Times, Fortis Healthcare, Dr Agarwal’s Healthcare, Manipal, Apollo Hospitals and Medanta were among the hospital companies affected by the sell-off. Fortis shares fell 10% over two sessions, while Apollo Hospitals Enterprises declined 9% and Max Healthcare dropped 8% over the same period. The immediate trigger was regulatory scrutiny, but the underlying concern is the gap between the price at which hospitals procure products and the price patients are charged.
The Supreme Court’s intervention has brought oncology pricing into particular focus. The report said the court flagged a tenfold difference in the price of a cancer drug, with the Price to Retailer listed at Rs 2,700 and the Maximum Retail Price at Rs 27,000. At a subsequent hearing, the Bench asked why a uniform 16% margin cap could not be enforced across pharma products. The questions do not, by themselves, establish a final regulatory rule, but they have placed hospital pricing practices under direct public and institutional scrutiny.
That scrutiny extends beyond cancer medicines. The Government of India has begun discussions with the medical sector and hospitals on rationalising trade margins for medical devices and consumables. The discussions followed reports of markups ranging from 10 to 20 times on hospital items after an FDA Commissioner highlighted the difference between trade prices and declared MRPs.
The products identified in the report include disposable syringes, intravenous sets, cardiac catheters, intraocular lenses, pacemakers and heart valves. These are not optional retail purchases in the usual sense. They are tied to procedures, emergency care, surgery and long-term treatment, which means patients often encounter their prices after a clinical decision has already been made and while the cost of delay may be high.
The FDA Commissioner has urged the Centre to frame guidelines addressing the permissible gap between trade procurement prices and declared MRPs. That proposal points to a regulatory problem involving more than hospital billing. It raises questions about how prices are formed across manufacturers, distributors, hospitals and pharmacies, and how much of that chain is visible to patients before treatment begins.
The pharmacy channel is important to the hospital business model. The report cited Emkay’s assessment that pharmacies account for 15% to 20% of overall hospital revenue and carry margins of 20% to 25%. Any intervention affecting medicine margins could therefore change the economics of hospital operations, although the effect would not be uniform across patients or companies.
Emkay said a margin cap would primarily affect cash-paying patients. Patients covered by insurance and public health schemes generally use pre-negotiated package rates, which are discounted from rack rates and tariffs rather than being calculated directly from headline MRPs. This distinction matters because a regulatory intervention may reduce the price burden for one group without automatically changing the price architecture experienced by another.
It also shows why a single margin rule may be difficult to apply across the healthcare ecosystem. Emkay does not expect a blanket cap on drug margins, citing executional and operational challenges in covering non-scheduled drugs across pharmaceutical companies, distributors and supply-chain players. The report does not provide details of a proposed framework, leaving the scope, coverage and enforcement mechanism unresolved.
For hospital companies, the immediate concern is the potential effect on earnings before interest, taxes, depreciation and amortisation. Oncology drugs account for 4% to 6% of hospital revenue, according to the report. The sector’s exposure to consumables, devices and pharmacy income means that even a rule aimed at one part of the value chain could affect hospital pricing, procedure tariffs and procurement practices elsewhere.
Brokerage assessments indicate that the market is attempting to distinguish between a direct earnings shock and a longer regulatory overhang. Jefferies retained a Buy call on six hospital stocks after the correction and said hospitals have several levers to offset the impact of potential price cuts. Its assessment referred to the earlier reduction of cardiac-stent and orthopaedic-knee-implant prices by 70% to 85% nearly a decade ago.
According to Jefferies, hospitals mitigated that earlier impact through staggered increases in procedure prices and cost-rationalisation measures over 12 to 15 months. Apollo Hospitals adopted comparable measures in 2017-18 and restored EBITDA margins to prior levels within a few quarters, the brokerage said. Whether that experience can be replicated depends on the final design of any intervention and on how much flexibility hospitals retain in setting procedure prices.
The comparison also highlights a structural feature of hospital pricing: the cost of a treatment is not limited to the medicine or device used during a procedure. It can include room charges, professional fees, diagnostics, consumables, pharmacy items and bundled tariffs. A change in one component can therefore lead hospitals to alter other components, even if the patient’s total bill does not move in the same proportion.
Jefferies said sector fundamentals remained supported by demand for quality tertiary-care beds. After the recent correction, hospital stocks were trading at implied FY28 EV-to-EBITDA valuations of 20 to 27 times, compared with 25 to 35 times a year earlier. The brokerage argued that companies capable of delivering sustainable high-teens EBITDA growth could view the correction as an entry point. These are market assessments, not evidence that patient costs will fall.
The distinction between investor confidence and patient affordability is central to the debate. A hospital may be able to protect margins through procedure pricing or operating efficiencies, while the patient may still face a complex and difficult-to-compare bill. Conversely, a reduction in medicine or consumable margins may not translate into an equivalent reduction in the total treatment cost if other charges change.
The regulatory challenge is therefore one of transparency as much as price control. The Supreme Court’s questions, the government’s discussions and the FDA Commissioner’s call for guidelines all point towards concern over the relationship between procurement prices, MRPs, hospital pharmacies and treatment charges. The supplied report does not establish whether hospitals universally compel patients to use designated pharmacies, nor does it quantify the practice across the sector. That allegation remains an issue for examination by the government.
The question of a uniform 16% margin cap also illustrates the tension between a simple rule and a complex supply chain. A cap may be easier for patients to understand, but implementation would have to account for product categories, scheduled and non-scheduled medicines, distributors, hospital procurement systems, insurance packages and public health schemes. The government’s discussions will determine whether the eventual framework focuses on margins, disclosure, procurement practices, patient choice or a combination of these mechanisms.
For cities, this is a healthcare infrastructure question as much as a stock-market story. Private hospitals are key providers of tertiary care, particularly for cancer treatment, cardiac procedures, ophthalmic surgery and other specialised services. When pricing rules change, the impact travels through hospital operations, household finances, insurers and public health systems. The affordability of urban healthcare is shaped not only by the number of beds available, but also by how the bill is assembled.
What the evidence currently confirms is narrower than the market reaction suggests. The Supreme Court has questioned steep oncology markups and asked the government to examine hospital pharmacy requirements. The Centre is discussing medical-sector margins, while brokerages differ on the likely earnings impact and on the feasibility of a blanket cap. The next decisive development will be the government’s regulatory response and any further court direction on the pricing and procurement practices under examination.